home / stock / cfrx / cfrx news

CFRX News and Press, ContraFect Corporation From 05/16/22

Stock Information
Company Name: ContraFect Corporation
Stock Symbol: CFRX
Market: NASDAQ
Website: contrafect.com
Menu
CFRX CFRX Quote CFRX Short CFRX News CFRX Articles CFRX Message Board
Get CFRX Alerts

News, Short Squeeze, Breakout and More Instantly...
CFRX - ContraFect Reports First Quarter 2022 Financial Results and Provides Business Update

YONKERS, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the...
CFRX - ContraFect Data Presentations at the 32nd Annual ECCMID Meeting Highlight the Potential of Engineered Lysin CF-370 to Improve Clinical Outcomes and Suppress Antimicrobial Resistance Compared to Antibiotics Alone

YONKERS, N.Y., April 27, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the t...

CFRX - ContraFect Announces Multiple Presentations of New Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Address Antimicrobial Resistance at the 32nd Annual ECCMID Meeting

YONKERS, N.Y., April 18, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the t...

CFRX - Shares of ContraFect Corporation (CFRX) Have Risen Above Previous 52-Week High

Shares of ContraFect Corporation (NASDAQ:CFRX) traded at a new 52-week high today of $13.05. Approximately 49.7 million shares have changed hands today, as compared to an average 30-day volume of 62,000 shares. In the past 52 weeks, shares of ContraFect Corporation have traded between th...
CFRX - Contrafect GAAP EPS of -$0.11 beats by $0.19

Contrafect press release (NASDAQ:CFRX): Q4 GAAP EPS of -$0.11 beats by $0.19. As of December 31, 2021, cash, cash equivalents and marketable securities of $54.3M. For further details see: Contrafect GAAP EPS of -$0.11 beats by $0.19

CFRX - ContraFect Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Business Update

YONKERS, N.Y., March 24, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for t...

CFRX - ContraFect to Present at the Maxim Group 2022 Virtual Growth Conference

YONKERS, N.Y., March 21, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the t...
CFRX - ContraFect (CFRX) Investor Presentation - Slideshow

The following slide deck was published by ContraFect Corporation in conjunction with this event. For further details see: ContraFect (CFRX) Investor Presentation - Slideshow

CFRX - ContraFect to Present at the SVB Leerink 11th Annual Global Healthcare Conference

YONKERS, N.Y., Feb. 10, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the tr...

CFRX - ContraFect Announces Award from the Cystic Fibrosis Foundation to Evaluate Exebacase as a Potential Treatment for Serious MRSA Lung Infections Associated with Cystic Fibrosis

YONKERS, N.Y., Jan. 06, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the tr...
Previous 10 Next 10